Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Cancer Immunol Immunother. 2018 Jan 13;67(4):639–652. doi: 10.1007/s00262-018-2115-2

Figure 2. Dual conditioning with ACT reduces disease burden in neoplastic islets.

Figure 2

a Inflammation scores in the periductal and acinar regions (pancreatitis) and islets (isletitis) from H&E-stained sections of whole pancreata harvested 7 days after the indicated treatments. N=4–6/group. b Representative H&E-stained section showing inflammation within a pancreatic carcinoma and adjacent pancreatic acinar compartment. c–h Representative H&E (c–e) and Masson’s trichrome stained (f–h) tumors harvested from untreated (c, f) or RT4 mice that received anti-CD40+TCR-I cells (d, g) or dual conditioning + TCR-I cells (e, h). i Highest disease stage observed 70 days after treatment, N=6–9/group. j Percentage hyperplastic islets in whole pancreas sections from mice shown in panel i that survived to day 70 post treatment. Each point represents an individual mouse. N=5–12/group; WBI+αCD40+TCR-I vs all other treatment groups, * p<0.05 by one way ANOVA with Dunnett’s post-test.